{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:52:31Z","timestamp":1779295951123,"version":"3.51.4"},"reference-count":180,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.hlc.2023.12.006","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T21:07:07Z","timestamp":1705612027000},"page":"605-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8046-500X","authenticated-orcid":false,"given":"Tingting","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.hlc.2023.12.006_bib1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjqcco\/qcac070","article-title":"European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment","volume":"9","author":"Lee","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Method"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"Prisma extension for scoping reviews (PRISMA-SCR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Int Med"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.63.2.368","article-title":"Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis","volume":"63","author":"Kim","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cdp.2004.07.008","article-title":"Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism","volume":"29","author":"Wold","year":"2005","journal-title":"Cancer Detect Prev"},{"issue":"9","key":"10.1016\/j.hlc.2023.12.006_bib9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.freeradbiomed.2006.08.006","article-title":"Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice","volume":"41","author":"Chen","year":"2006","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"H1273","DOI":"10.1152\/ajpheart.00738.2005","article-title":"DNA damage is an early event in doxorubicin-induced cardiac myocyte death","volume":"291","author":"L'Ecuyer","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/emm.2006.63","article-title":"Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes","volume":"38","author":"Kim","year":"2006","journal-title":"Exp Mol Med"},{"issue":"18","key":"10.1016\/j.hlc.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.freeradbiomed.2006.11.013","article-title":"Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH","volume":"42","author":"Deng","year":"2007","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12012-007-0026-0","article-title":"Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment","volume":"7","author":"Berthiaume","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.2006.0161","article-title":"Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death","volume":"27","author":"Chiosi","year":"2007","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/cvr\/cvn076","article-title":"Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes","volume":"79","author":"Yamamoto","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cbi.2008.09.012","article-title":"Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation","volume":"177","author":"Bernuzzi","year":"2009","journal-title":"Chem Biol Interact"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbrc.2009.08.085","article-title":"NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis","volume":"388","author":"Gilleron","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib19","doi-asserted-by":"crossref","first-page":"H1832","DOI":"10.1152\/ajpheart.01047.2009","article-title":"Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice","volume":"298","author":"Vedam","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.taap.2009.09.012","article-title":"Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats","volume":"242","author":"Zordoky","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"issue":"9","key":"10.1016\/j.hlc.2023.12.006_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012733","article-title":"Doxorubicin in\u00a0vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation","volume":"5","author":"Pointon","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1248\/bpb.33.1666","article-title":"Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A","volume":"33","author":"Tan","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"20","key":"10.1016\/j.hlc.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1158\/0008-5472.CAN-10-3397","article-title":"Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism","volume":"71","author":"Huang","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hlc.2023.12.006_bib24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","article-title":"Doxorubicin and daunorubicin induce processing and release of interleukin-1\u03b2 through activation of the NLRP3 inflammasome","volume":"11","author":"Sauter","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018005","article-title":"p53 regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury","volume":"6","author":"Velez","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.yjmcc.2011.05.010","article-title":"Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy","volume":"51","author":"van Almen","year":"2011","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022801","article-title":"Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes","volume":"6","author":"Feridooni","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvq361","article-title":"Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart","volume":"90","author":"Park","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1258\/ebm.2011.011106","article-title":"Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart","volume":"237","author":"Sishi","year":"2012","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035743","article-title":"Disruption of a GATA4\/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00441-012-1475-8","article-title":"Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes","volume":"350","author":"Dimitrakis","year":"2012","journal-title":"Cell Tissue Res"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000343000","article-title":"Urokinase receptor mediates doxorubicin-induced vascular smooth muscle cell senescence via proteasomal degradation of TRF2","volume":"50","author":"Hodjat","year":"2013","journal-title":"J\u00a0Vasc Res"},{"issue":"17","key":"10.1016\/j.hlc.2023.12.006_bib33","first-page":"2323","article-title":"Doxorubicin-induced apoptosis in H9c2 cardiomyocytes by NF-\u03baB dependent PUMA upregulation","volume":"17","author":"Li","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.hlc.2023.12.006_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tox.2013.04.016","article-title":"Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity","volume":"309","author":"Sishi","year":"2013","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/mmr.2013.1554","article-title":"Activation of the p38 MAPK\/NF-\u03baB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells","volume":"8","author":"Guo","year":"2013","journal-title":"Mol Med Rep"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib36","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/0008-5472.CAN-12-3453","article-title":"G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin","volume":"73","author":"Yang","year":"2013","journal-title":"Cancer Res"},{"issue":"51","key":"10.1016\/j.hlc.2023.12.006_bib37","doi-asserted-by":"crossref","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","article-title":"Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling","volume":"111","author":"Dhingra","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.taap.2013.10.023","article-title":"Keap1 redox-dependent regulation of doxorubicin-induced oxidative stress response in cardiac myoblasts","volume":"274","author":"Nordgren","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131763","article-title":"Dissecting the mechanisms of doxorubicin and oxidative stress-induced cytotoxicity: the involvement of actin cytoskeleton and ROCK1","volume":"10","author":"Wei","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib40","first-page":"12216","article-title":"Effects of PPAR\u03b1\/PGC-1\u03b1 on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in\u00a0vitro","volume":"8","author":"Yang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"35","key":"10.1016\/j.hlc.2023.12.006_bib41","doi-asserted-by":"crossref","first-page":"37443","DOI":"10.18632\/oncotarget.5338","article-title":"The regulatory mechanisms of myogenin expression in doxorubicin-treated rat cardiomyocytes","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.hlc.2023.12.006_bib42","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1042\/BCJ20160385","article-title":"Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy","volume":"473","author":"Bartlett","year":"2016","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1242\/bio.020362","article-title":"Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability","volume":"5","author":"Wilkinson","year":"2016","journal-title":"Biol Open"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177660","article-title":"Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits","volume":"12","author":"Ichikawa","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.hlc.2023.12.006_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biocel.2017.05.006","article-title":"Doxorubicin-induced cardiomyocyte apoptosis: Role of mitofusin 2","volume":"88","author":"Tang","year":"2017","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.hlc.2023.12.006_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2018.04.009","article-title":"Doxorubicin triggers bioenergetic failure and p53 activation in mouse\u00a0stem cell-derived cardiomyocytes","volume":"348","author":"Cunha-Oliveira","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcp.25905","article-title":"Mitochondrial ROS-induced ERK1\/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity","volume":"233","author":"Huang","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.hlc.2023.12.006_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8949450","article-title":"Ex\u00a0vivo cardiotoxicity of antineoplastic casiopeinas is mediated through energetic dysfunction and triggered mitochondrial-dependent apoptosis","volume":"2018","author":"Silva-Platas","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.hlc.2023.12.006_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tiv.2018.05.001","article-title":"Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1\/parkin pathway","volume":"51","author":"Yin","year":"2018","journal-title":"Toxicol In\u00a0Vitro"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215992","article-title":"CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression","volume":"14","author":"Tscheschner","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib51","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.hlc.2018.08.003","article-title":"Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts","volume":"28","author":"Levick","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib52","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1096\/fj.201802663R","article-title":"Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy","volume":"33","author":"Catanzaro","year":"2019","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib53","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3892\/ijmm.2020.4669","article-title":"Doxorubicin-induced oxidative and nitrosative stress: mitochondrial connexin 43 is at the crossroads","volume":"46","author":"Pecoraro","year":"2020","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib54","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.31788\/RJC.2020.1325603","article-title":"Anti-cancer drug doxorubicin induced cardiotoxicity: understanding the mechanisms involved in ROS generation resulting in mitochondrial dysfunction","volume":"13","author":"Upadhayay","year":"2020","journal-title":"Rasayan J Chem"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib55","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cvr\/cvz240","article-title":"Impaired NF-\u03baB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy","volume":"116","author":"Dhingra","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.hlc.2023.12.006_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238856","article-title":"Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts","volume":"15","author":"Mancilla","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169756","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"8","author":"Tadokoro","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","article-title":"Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity","volume":"20","author":"Wei","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hlc.2023.12.006_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110525","article-title":"NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity","volume":"130","author":"Xu","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12012-020-09581-7","article-title":"Disruption of the Keap1\/Nrf2-Antioxidant Response System After Chronic Doxorubicin Exposure In\u00a0Vivo","volume":"20","author":"Nordgren","year":"2020","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ehf2.12616","article-title":"Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12012-020-09606-1","article-title":"Doxorubicin cytotoxicity in differentiated H9c2 cardiomyocytes: evidence for acute mitochondrial superoxide generation","volume":"21","author":"Helal","year":"2021","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hlc.2023.12.006_bib63","article-title":"PKC-\u03b6 aggravates doxorubicin-induced cardiotoxicity by inhibiting Wnt\/\u03b2-catenin signaling","volume":"13","author":"Cao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hlc.2023.12.006_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2022.153113","article-title":"ROS and iron homeostasis dependent ferroptosis play a vital role in 5-fluorouracil induced cardiotoxicity in\u00a0vitro and in\u00a0vivo","volume":"468","author":"Li","year":"2022","journal-title":"Toxicology"},{"issue":"19","key":"10.1016\/j.hlc.2023.12.006_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911098","article-title":"Neurotoxic effect of doxorubicin treatment on cardiac sympathetic neurons","volume":"23","author":"Moro","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib66","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1124\/mol.108.050104","article-title":"Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib","volume":"74","author":"Hasinoff","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.taap.2011.08.020","article-title":"Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations","volume":"257","author":"Cohen","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","article-title":"Mechanisms of cardiotoxicity associated with ErbB2 inhibitors","volume":"134","author":"Fedele","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"187","key":"10.1016\/j.hlc.2023.12.006_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12012-014-9266-y","article-title":"Mitogen-activated protein kinases pathways mediate the sunitinib-induced hypertrophy in rat cardiomyocyte H9c2 cells","volume":"15","author":"Korashy","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hlc.2023.12.006_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxlet.2016.04.011","article-title":"Molecular mechanisms of cardiotoxicity of gefitinib in\u00a0vivo and in\u00a0vitro rat cardiomyocyte: role of apoptosis and oxidative stress","volume":"252","author":"Korashy","year":"2016","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.hlc.2023.12.006_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2015.11.007","article-title":"Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: protective role of L-carnitine","volume":"241","author":"Blanca","year":"2016","journal-title":"Toxicol Lett"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib74","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hlc.2023.12.006_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2019.152281","article-title":"Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib","volume":"426","author":"Bouitbir","year":"2019","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/cancers11040571","article-title":"Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles","volume":"11","author":"Huot","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12012-020-09565-7","article-title":"Mechanisms of the cardiac myocyte-damaging effects of dasatinib","volume":"20","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hlc.2023.12.006_bib78","doi-asserted-by":"crossref","first-page":"104926","DOI":"10.1016\/j.tiv.2020.104926","article-title":"Trastuzumab-induced cardiotoxicity and role of mitochondrial connexin43 in the adaptive response","volume":"67","author":"Pecoraro","year":"2020","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bcpt.13318","article-title":"Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis","volume":"126","author":"Ma","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.hlc.2023.12.006_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115577","article-title":"Mitochondrial dynamics imbalance and mitochondrial dysfunction contribute to the molecular cardiotoxic effects of lenvatinib","volume":"423","author":"Gunaydin Akyildiz","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.hlc.2023.12.006_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115852","article-title":"Role of ferroptosis in promoting cardiotoxicity induced by imatinib mesylate via down-regulating Nrf2 pathways in\u00a0vitro and in\u00a0vivo","volume":"435","author":"Song","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib82","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/15548627.2021.1965712","article-title":"Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib","volume":"18","author":"Xu","year":"2022","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib83","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.3390\/ijms23042282","article-title":"Mitochondrial toxicity associated with imatinib and sorafenib in isolated rat heart fibers and the cardiomyoblast H9c2 cell line","volume":"23","author":"Bouitbir","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib84","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaccao.2022.07.009","article-title":"Cellular and molecular mechanisms of MEK1 inhibitor-induced cardiotoxicity","volume":"4","author":"Beck","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hlc.2023.12.006_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.toxlet.2022.06.001","article-title":"Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis","volume":"365","author":"Cui","year":"2022","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.hlc.2023.12.006_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2022.153348","article-title":"Impaired autophagy and mitochondrial dynamics are involved in sorafenib-induced cardiomyocyte apoptosis","volume":"481","author":"Liang","year":"2022","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3892\/ijmm.2021.5072","article-title":"Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells","volume":"49","author":"Sun","year":"2022","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.hlc.2023.12.006_bib88","article-title":"Bevacizumab-induced mitochondrial dysfunction, endoplasmic reticulum stress, and ERK inactivation contribute to cardiotoxicity","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib90","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-20-3882","article-title":"A\u00a0novel mouse model of radiation-induced cardiac injury reveals biological and radiological biomarkers of cardiac dysfunction with potential clinical relevance","volume":"27","author":"Dreyfuss","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib91","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220809","article-title":"Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies","volume":"220","author":"Shamseddine","year":"2023","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib92","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1253\/circj.68.163","article-title":"Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats","volume":"68","author":"Koh","year":"2004","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib93","first-page":"246","article-title":"Identification of marker genes related to cardiovascular toxicity of doxorubicin and daunorubicin in human umbilical vein endothelial cells (HUVECs)","volume":"3","author":"Kim","year":"2007","journal-title":"Mol Cell Toxicol"},{"issue":"4\u20136","key":"10.1016\/j.hlc.2023.12.006_bib94","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.vph.2008.07.004","article-title":"Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells","volume":"49","author":"Zordoky","year":"2008","journal-title":"Vascul Pharmacol"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib96","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","article-title":"Early biomarkers of doxorubicin-induced heart injury in a mouse model","volume":"281","author":"Desai","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib97","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/1354750X.2014.885084","article-title":"The decrease of NAD(P)H:quinone oxidoreductase 1 activity and increase of ROS production by NADPH oxidases are early biomarkers in doxorubicin cardiotoxicity","volume":"19","author":"Lagoa","year":"2014","journal-title":"Biomarkers"},{"key":"10.1016\/j.hlc.2023.12.006_bib98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tox.2014.12.018","article-title":"Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells","volume":"328","author":"Holmgren","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.hlc.2023.12.006_bib99","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13014-016-0627-5","article-title":"Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study","volume":"11","author":"Jacob","year":"2016","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib100","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00204-015-1623-5","article-title":"Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in\u00a0vitro repeated exposure toxicity approach for safety assessment","volume":"90","author":"Chaudhari","year":"2016","journal-title":"Arch Toxicol"},{"issue":"12","key":"10.1016\/j.hlc.2023.12.006_bib101","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00204-016-1668-0","article-title":"MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"90","author":"Chaudhari","year":"2016","journal-title":"Arch Toxicol"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib102","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/toxsci\/kfz026","article-title":"Early cardiac mitochondrial molecular and functional responses to acute anthracycline treatment in Wistar rats","volume":"169","author":"Pereira","year":"2019","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.hlc.2023.12.006_bib104","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41420-019-0182-6","article-title":"Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity","volume":"5","author":"McSweeney","year":"2019","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.hlc.2023.12.006_bib105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2020.04.018","article-title":"Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity","volume":"152","author":"Unger","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/mmr.2020.11752","article-title":"The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin-induced cardiotoxicity","volume":"23","author":"Kanno","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.hlc.2023.12.006_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.737826","article-title":"microRNA-377 signaling modulates anticancer drug-induced cardiotoxicity in mice","volume":"8","author":"Henderson","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib108","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/biom11111725","article-title":"Role of inflammation and redox status on doxorubicin-induced cardiotoxicity in infant and adult CD-1 male mice","volume":"11","author":"Reis-Mendes","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.hlc.2023.12.006_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.695625","article-title":"Translational proteomics analysis of anthracycline-induced cardiotoxicity from cardiac microtissues to human heart biopsies","volume":"12","author":"Nguyen","year":"2021","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ncrna.2022.01.002","article-title":"Transcriptome analysis of long noncoding RNAs reveals their potential roles in anthracycline-induced cardiotoxicity","volume":"7","author":"Nguyen","year":"2022","journal-title":"Noncoding RNA Res"},{"issue":"12","key":"10.1016\/j.hlc.2023.12.006_bib111","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.3390\/cancers14122941","article-title":"A\u00a0fibrosis biomarker early predicts cardiotoxicity due to anthracycline-based breast cancer chemotherapy","volume":"14","author":"de la Fuente","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib112","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/jat.4257","article-title":"Integrating analysis of circular RNA and mRNA expression profiles in doxorubicin induced cardiotoxicity mice","volume":"42","author":"Xing","year":"2022","journal-title":"J\u00a0Appl Toxicol"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib113","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/ehf2.14034","article-title":"Histopathological and epigenetic changes in myocardium associated with cancer therapy-related cardiac dysfunction","volume":"9","author":"Terada","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hlc.2023.12.006_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in\u00a0vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib116","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","article-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","volume":"200","author":"Oliveira","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.hlc.2023.12.006_bib117","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"issue":"1\u20132","key":"10.1016\/j.hlc.2023.12.006_bib118","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.hlc.2023.12.006_bib119","doi-asserted-by":"crossref","first-page":"1089359","DOI":"10.1155\/2017\/1089359","article-title":"Cardiac nonmyocyte cell functions and crosstalks in response to cardiotoxic drugs","volume":"2017","author":"Gambardella","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib121","first-page":"7833","article-title":"Localization and dynamic changes of neuregulin-1 at C-type synaptic boutons in association with","volume":"33","author":"Salvany","year":"2019","journal-title":"motor neuron injury and repair. FASEB J"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib122","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/membranes4030424","article-title":"The mysterious ways of ErbB2\/HER2 trafficking","volume":"4","author":"Bertelsen","year":"2014","journal-title":"Membranes (Basel)"},{"issue":"6924","key":"10.1016\/j.hlc.2023.12.006_bib123","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib124","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib125","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jcmm.13408","article-title":"Neuregulin-1 is essential for nerve plexus formation during cardiac maturation","volume":"22","author":"Brown","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib126","first-page":"2311","article-title":"Neuregulin-1: an underlying protective force of cardiac dysfunction in sepsis (Review)","volume":"21","author":"Kang","year":"2020","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib127","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.hlc.2023.12.006_bib128","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib129","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0008-6363(98)00228-4","article-title":"Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells","volume":"41","author":"Bouloumi\u00e9","year":"1999","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01481-6","article-title":"Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42\/p44 mitogen-activated protein kinase","volume":"420","author":"Wheeler-Jones","year":"1997","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccc.2020.08.003","article-title":"Toxicities associated with immunotherapy and approach to cardiotoxicity with novel cancer therapies","volume":"37","author":"Gutierrez","year":"2021","journal-title":"Crit Care Clin"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib133","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"6382","key":"10.1016\/j.hlc.2023.12.006_bib134","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/713774061","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"Microcirculation"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib136","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib137","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib138","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.hlc.2023.12.006_bib139","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"3\u20134","key":"10.1016\/j.hlc.2023.12.006_bib141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000510573","article-title":"Modern radiotherapy and risk of cardiotoxicity","volume":"65","author":"Koutroumpakis","year":"2020","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib142","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/HCO.0000000000000404","article-title":"Radiotherapy, chemotherapy and atherosclerosis","volume":"32","author":"Min","year":"2017","journal-title":"Curr Opin Cardiol"},{"issue":"6\u20137","key":"10.1016\/j.hlc.2023.12.006_bib143","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.canrad.2020.07.001","article-title":"Radio-induced cardiotoxicity: from physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up","volume":"24","author":"Kirova","year":"2020","journal-title":"Cancer Radiother"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib144","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-associated cardiac disease: a practical approach to diagnosis and management","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2011.06.016","article-title":"Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden","volume":"100","author":"McGale","year":"2011","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib146","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jjcc.2018.10.009","article-title":"Risk of cardiovascular disease after radiotherapy in survivors of breast cancer: A case-cohort study","volume":"73","author":"Hamood","year":"2019","journal-title":"J Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib147","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ijrobp.2018.11.013","article-title":"Early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy for breast cancer, lung cancer, and lymphoma","volume":"103","author":"Demissei","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib148","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.blre.2016.08.004","article-title":"Placental growth factor: what hematologists need to know","volume":"31","author":"Newell","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.hlc.2023.12.006_bib149","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.preghy.2018.03.003","article-title":"Placental growth factor: a review of literature and future applications","volume":"14","author":"Hayes Ryan","year":"2018","journal-title":"Pregnancy Hypertens"},{"issue":"5","key":"10.1016\/j.hlc.2023.12.006_bib150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib151","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/14728222.2014.948420","article-title":"Placental growth factor in cancer","volume":"18","author":"Dewerchin","year":"2014","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib152","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/erm.10.11","article-title":"Micromarkers: miRNAs in cancer diagnosis and prognosis","volume":"10","author":"Ferracin","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.hlc.2023.12.006_bib153","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2007.097972","article-title":"Detection and characterization of placental microRNAs in maternal plasma","volume":"54","author":"Chim","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.hlc.2023.12.006_bib154","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1476-4598-9-306","article-title":"Serum microRNAs as non-invasive biomarkers for cancer","volume":"9","author":"Brase","year":"2010","journal-title":"Mol Cancer"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib155","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1373\/clinchem.2009.125310","article-title":"Plasma miR-208 as a biomarker of myocardial injury","volume":"55","author":"Ji","year":"2009","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.hlc.2023.12.006_bib156","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1373\/clinchem.2010.144121","article-title":"Plasma microRNA 499 as a biomarker of acute myocardial infarction","volume":"56","author":"Adachi","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.hlc.2023.12.006_bib157","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.redox.2017.12.013","article-title":"MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2","volume":"15","author":"Zhao","year":"2018","journal-title":"Redox Biol"},{"issue":"9","key":"10.1016\/j.hlc.2023.12.006_bib158","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41419-019-1901-x","article-title":"miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b\/P53 pathway in doxorubicin-induced cardiotoxicity","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib159","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.hlc.2023.12.006_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004612","article-title":"Computational model of MicroRNA control of HIF-VEGF pathway: insights into the pathophysiology of ischemic vascular disease and cancer","volume":"11","author":"Zhao","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib161","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1159\/000485949","article-title":"Exosomes from MiR-126-overexpressing Adscs are therapeutic in relieving acute myocardial ischaemic injury","volume":"44","author":"Luo","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"22","key":"10.1016\/j.hlc.2023.12.006_bib162","first-page":"5096","article-title":"Experimental study on the prevention of liver cancer angiogenesis via miR-126","volume":"21","author":"Jing","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.hlc.2023.12.006_bib163","first-page":"4987","article-title":"Let-7f and miRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy","volume":"11","author":"Zhu","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib164","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12291-022-01075-3","article-title":"Evaluation of expression level of miR-3135b-5p in blood samples of breast cancer patients experiencing chemotherapy-induced cardiotoxicity","volume":"38","author":"Zare","year":"2023","journal-title":"Indian J Clin Biochem"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib165","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib166","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","article-title":"Galectin-3--a jack-of-all-trades in cancer","volume":"313","author":"Newlaczyl","year":"2011","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib167","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1535370215593826","article-title":"Galectin-3 in autoimmunity and autoimmune diseases","volume":"240","author":"de Oliveira","year":"2015","journal-title":"Exp Biol Med (Maywood)"},{"issue":"8","key":"10.1016\/j.hlc.2023.12.006_bib168","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2023.12.006_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131386","article-title":"Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice","author":"Seropian","year":"2023","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.12.006_bib170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2015.246553","article-title":"Short-and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults","volume":"62","author":"Schindler","year":"2016","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib171","first-page":"445","article-title":"Fibrotic marker galectin-3 identifies males at risk of developing cancer and heart failure","volume":"5","author":"van den Berg","year":"2023","journal-title":"J Am Coll Cardiol CardioOnc"},{"issue":"4","key":"10.1016\/j.hlc.2023.12.006_bib172","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaccao.2023.06.001","article-title":"Galectin-3 and risk for cancer or heart failure: does sex matter?","volume":"5","author":"Fabiani","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hlc.2023.12.006_bib173","doi-asserted-by":"crossref","first-page":"6258865","DOI":"10.1155\/2021\/6258865","article-title":"A review of novel cardiac biomarkers in acute or chronic cardiovascular diseases: the role of soluble ST2 (sST2), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT)","volume":"2021","author":"Li","year":"2021","journal-title":"Dis Markers"},{"key":"10.1016\/j.hlc.2023.12.006_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-800096-0.00001-9","article-title":"Myeloperoxidase in cardiovascular disease","volume":"62","author":"Koeth","year":"2013","journal-title":"Adv Clin Chem"},{"issue":"12","key":"10.1016\/j.hlc.2023.12.006_bib175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000090690.67322.51","article-title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes","volume":"108","author":"Baldus","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2023.12.006_bib176","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1373\/clinchem.2009.142257","article-title":"Use of myeloperoxidase for risk stratification in acute heart failure","volume":"56","author":"Reichlin","year":"2010","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"10.1016\/j.hlc.2023.12.006_bib177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2011.10.009","article-title":"Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina","volume":"413","author":"Tretjakovs","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib178","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00395-023-01006-0","article-title":"Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy","volume":"118","author":"Nettersheim","year":"2023","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.12.006_bib179","first-page":"23","article-title":"Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy-a prospective analysis","volume":"9","author":"Dean","year":"2023","journal-title":"Cardiooncology"},{"issue":"18","key":"10.1016\/j.hlc.2023.12.006_bib180","first-page":"1621","volume":"44","author":"Lyon","year":"2023","journal-title":"J"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623044645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623044645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:33:09Z","timestamp":1728988389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950623044645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":180,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1443950623044645"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2023.12.006","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}